Cullinan Therapeutics (Nasdaq: CGEM) announced on July 28 that the FDA endorsed its Phase II development strategy for CLN-049, a FLT3×CD3 bispecific T cell engager for relapsed/refractory acute myeloid leukemia — clearing the path to a potentially registrational single-arm study that the Cambridge, Massachusetts-based company plans to initiate in Q3 2026. AML remains one of the few hematologic malignancies without an approved immunotherapy, and CLN-049's mechanism — simultaneously binding FLT3 on leukemic blasts and CD3 on T cells to redirect cytotoxic killing — operates independently of FLT3 mutational status, making it applicable to a broader patient population than existing targeted agents.
The agreed study design incorporates a short dose-optimization phase with seamless progression to a single-arm cohort at the recommended Phase II dose. CLN-049 holds both Orphan Drug and Fast Track designations from the FDA for relapsed/refractory AML. Phase I data presented at the 2025 American Society of Hematology Annual Meeting demonstrated promising clinical activity and a favorable safety profile, though Cullinan has not yet disclosed specific response rates; an update from the dose escalation portion of the ongoing Phase I study in relapsed/refractory AML and MDS is expected in Q4 2026.
In parallel, Cullinan plans to initiate a Phase I/II combination study evaluating CLN-049 with venetoclax and azacitidine in previously untreated AML, layering the T cell engager onto the standard-of-care backbone for unfit patients — AbbVie's Venclexta (venetoclax) plus azacitidine — to test whether immune-mediated cytotoxicity can deepen responses in the frontline setting.
The competitive backdrop is relevant. Approved FLT3-directed agents — Astellas's Xospata (gilteritinib) for relapsed/refractory FLT3-mutated AML, and Daiichi Sankyo's Vanflyta (quizartinib) for newly diagnosed FLT3-ITD disease — are restricted to mutation-positive patients. CLN-049's pan-FLT3 binding, covering both mutated and non-mutated receptor, could extend eligibility across roughly 70–90% of AML cases. No T cell engager is currently approved in AML; the class has established proof of concept in B cell malignancies but has faced challenges translating to myeloid disease, making the FDA's alignment on a registrational design a meaningful signal for the field.